Chemours (CC) Could Be 25% Undervalued After The Opteon Demand Lawsuit

Chemours lawsuit puts Opteon demand assumptions under the microscope

Chemours (CC) is in focus after a new securities class action accused the business of overstating aftermarket demand for its Opteon refrigerants and issuing unreliable 2026 financial guidance.

Recent trading has reflected this legal overhang, with Chemours’ share price down 4.85% over the past week and 11.16% over 30 days. The 1 year total shareholder return declined 2.20%, and the 5 year total shareholder return fell 48.83%, indicating weakening long term momentum.

Spot opportunities beyond Chemours by scanning a hand-picked 33 high quality undervalued stocks that combines resilient cash flows with balance sheets designed to better withstand shocks such as legal and demand surprises.

The lawsuit, falling returns and renewed patent push leave Chemours trading at levels that some see as business risk and others read as sentiment fatigue. Which of those stories does the current valuation actually tell?

Most Popular Narrative: 25% Undervalued

Chemours closed at $12.74, while the most followed narrative pegs fair value at $16.90, so the lawsuit now collides with a valuation story built on earnings quality, cash flow and product mix rather than hype around a single refrigerant line.

Execution on the Pathway to Thrive program, including guidance for adjusted EBITDA of US$775m to US$825m in 2026, a medium term target of at least US$1b adjusted EBITDA with more than 40% free cash flow conversion, and actions that have addressed close to US$2b of near term debt while aiming for net leverage around 3.8x, supports the case that Chemours can gradually improve earnings stability and free cash flow over time.

See why 13 investors see Chemours as 25% undervalued.

Result: Fair Value of $16.90 (UNDERVALUED)

Still, Chemours faces two big swing factors: unresolved PFAS liabilities that could keep dragging on cash, and refrigerant rule changes that may slow Opteon adoption.

Find out about the key risks to this Chemours narrative.

Next Steps

Sentiment around Chemours appears clearly split, and that kind of gap between concern and optimism rarely lasts. Consider acting promptly, review the full risk and reward breakdown, and ground your own view in the 3 key rewards and 2 important warning signs.

Looking for more Chemours-sized opportunities?

Do not stop with Chemours. Broaden your watchlist with focused ideas that filter for quality, resilience and income so you are not relying on a single storyline.

• Target higher potential by scanning a focused group of smaller companies through the 14 elite penny stocks with strong financials that might sit off the usual radar.
• Strengthen your income stream by reviewing the 8 dividend fortresses that filters for companies offering yields above 5% with an emphasis on stability.
• Reduce portfolio shocks by concentrating on the 32 resilient stocks with low risk scores that highlights businesses screened for resilient balance sheets and lower risk profiles.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com